AAAAAA

   
Results: 1-25 | 26-50 | 51-74
Results: 1-25/74
Factors predictive of outcome in patients with breast cancer refractory toneoadjuvant chemotherapy
Authors: Buchholz, TA Hill, BS Tucker, SL Frye, DK Kuerer, HM Buzdar, AU McNeese, MD Singletary, SE Ueno, NT Pusztai, L Valero, V Hortobagyi, GN
Citation: Ta. Buchholz et al., Factors predictive of outcome in patients with breast cancer refractory toneoadjuvant chemotherapy, CANCER J, 7(5), 2001, pp. 413-420
Adjuvant systemic therapy for early breast cancer: Progress and controversies
Authors: Hortobagyi, GN
Citation: Gn. Hortobagyi, Adjuvant systemic therapy for early breast cancer: Progress and controversies, CLIN CANC R, 7(7), 2001, pp. 1839-1842
Treatment of advanced breast cancer with gemcitabine and vinorelbine
Authors: Hortobagyi, GN Connally, NB
Citation: Gn. Hortobagyi et Nb. Connally, Treatment of advanced breast cancer with gemcitabine and vinorelbine, ONCOLOGY-NY, 15(2), 2001, pp. 15-17
Phase I-II vinorelbine (Navelbine((R))) by continuous infusion in patientswith metastatic breast cancer: Cumulative toxicities limit dose escalation
Authors: Ibrahim, NK Valero, V Rahman, Z Theriault, RL Walters, RS Buzdar, AU Booser, DJ Holmes, FA Murray, DJ Willey, J Bast, R Hortobagyi, GN
Citation: Nk. Ibrahim et al., Phase I-II vinorelbine (Navelbine((R))) by continuous infusion in patientswith metastatic breast cancer: Cumulative toxicities limit dose escalation, CANCER INV, 19(5), 2001, pp. 459-466
Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy
Authors: Buchholz, TA Tucker, SL Erwin, J Mathur, D Strom, EA McNeese, MD Hortobagyi, GN Cristofanilli, M Esteva, FJ Newman, L Singletary, SE Buzdar, AU Hunt, KK
Citation: Ta. Buchholz et al., Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy, J CL ONCOL, 19(8), 2001, pp. 2240-2246
Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer
Authors: Rivera, E Valero, V Syrewicz, L Rahman, Z Esteva, FL Theriault, RL Rosales, MM Booser, D Murray, JL Bast, RC Hortobagyi, GN
Citation: E. Rivera et al., Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer, J CL ONCOL, 19(6), 2001, pp. 1716-1722
Long-term results of combined-modality therapy for locally advanced breastcancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience
Authors: Brito, RA Valero, V Buzdar, AU Booser, DJ Ames, F Strom, E Ross, M Theriault, RL Frye, D Kau, SW Asmar, L McNeese, M Singletary, SE Hortobagyi, GN
Citation: Ra. Brito et al., Long-term results of combined-modality therapy for locally advanced breastcancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience, J CL ONCOL, 19(3), 2001, pp. 628-633
E1A is an oncogene and may immortalize normal cells, especially in combination with other oncoproteins - In reply
Authors: Hortobagyi, GN Ueno, N Hung, MC
Citation: Gn. Hortobagyi et al., E1A is an oncogene and may immortalize normal cells, especially in combination with other oncoproteins - In reply, J CL ONCOL, 19(21), 2001, pp. 4183-4184
Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: A phase I clinical trial
Authors: Hortobagyi, GN Ueno, NT Xia, WY Zhang, S Wolf, JK Putnam, JB Weiden, PL Willey, JS Carey, M Branham, DL Payne, JY Tucker, SD Bartholomeusz, C Kilbourn, RG De Jager, RL Sneige, N Katz, RL Anklesaria, P Ibrahim, NK Murray, JL Theriault, RL Valero, V Gershenson, DM Bevers, MW Huang, L Lopez-Berestein, G Hung, MC
Citation: Gn. Hortobagyi et al., Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: A phase I clinical trial, J CL ONCOL, 19(14), 2001, pp. 3422-3433
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification
Authors: Seidman, AD Fornier, MN Esteva, FJ Tan, L Kaptain, S Bach, A Panageas, KS Arroyo, C Valero, V Currie, V Gilewski, T Theodoulou, M Moynahan, ME Moasser, M Sklarin, N Dickler, M D'Andrea, G Cristofanilli, M Rivera, E Hortobagyi, GN Norton, L Hudis, CA
Citation: Ad. Seidman et al., Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification, J CL ONCOL, 19(10), 2001, pp. 2587-2595
Targeted therapies in the treatment of breast cancer - Introduction
Authors: Hortobagyi, GN
Citation: Gn. Hortobagyi, Targeted therapies in the treatment of breast cancer - Introduction, SEMIN ONCOL, 28(5), 2001, pp. 1-3
Optimal duration of therapy with trastuzumab
Authors: Hortobagyi, GN
Citation: Gn. Hortobagyi, Optimal duration of therapy with trastuzumab, SEMIN ONCOL, 28(5), 2001, pp. 33-40
Integration of trastuzumab into adjuvant systemic therapy of breast cancer: Ongoing and planned clinical trials
Authors: Hortobagyi, GN Perez, EA
Citation: Gn. Hortobagyi et Ea. Perez, Integration of trastuzumab into adjuvant systemic therapy of breast cancer: Ongoing and planned clinical trials, SEMIN ONCOL, 28(5), 2001, pp. 41-46
The evolving role of bisphosphonates
Authors: Theriault, RL Hortobagyi, GN
Citation: Rl. Theriault et Gn. Hortobagyi, The evolving role of bisphosphonates, SEMIN ONCOL, 28(3), 2001, pp. 284-290
Unmet needs in metastatic bone disease and its complications: Is progress possible?
Authors: Hortobagyi, GN
Citation: Gn. Hortobagyi, Unmet needs in metastatic bone disease and its complications: Is progress possible?, SEMIN ONCOL, 28(2), 2001, pp. 1-3
Paclitaxel in the multimodality treatment for inflammatory breast carcinoma
Authors: Cristofanilli, M Buzdar, AU Sneige, N Smith, T Wasaff, B Ibrahim, N Booser, D Rivera, E Murray, JL Valero, V Ueno, N Singletary, ES Hunt, K Strom, E McNeese, M Stelling, C Hortobagyi, GN
Citation: M. Cristofanilli et al., Paclitaxel in the multimodality treatment for inflammatory breast carcinoma, CANCER, 92(7), 2001, pp. 1775-1782
Breast conservation therapy as a treatment option for the elderly - The M.D. Anderson experience
Authors: Vlastos, G Mirza, NQ Meric, F Hunt, KK Kuerer, HM Ames, FC Ross, MI Buchholz, TA Hortobagyi, GN Singletary, SE
Citation: G. Vlastos et al., Breast conservation therapy as a treatment option for the elderly - The M.D. Anderson experience, CANCER, 92(5), 2001, pp. 1092-1100
Female patients with breast carcinoma age 30 years and younger have a poorprognosis - The M. D. Anderson Cancer Center Experience
Authors: Xiong, QH Valero, V Kau, V Kau, SW Taylor, S Smith, TL Smith, TL Buzdar, AU Hortobagyi, GN Theriault, RL
Citation: Qh. Xiong et al., Female patients with breast carcinoma age 30 years and younger have a poorprognosis - The M. D. Anderson Cancer Center Experience, CANCER, 92(10), 2001, pp. 2523-2528
Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma
Authors: Ibrahim, NK Buzdar, AU Valero, V Dhingra, K Willey, J Hortobagyi, GN
Citation: Nk. Ibrahim et al., Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma, CANCER, 91(4), 2001, pp. 664-671
Chemotherapy for breast cancer
Authors: Green, MC Hortobagyi, GN
Citation: Mc. Green et Gn. Hortobagyi, Chemotherapy for breast cancer, MDA CANC CA, 2001, pp. 309-341
Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma
Authors: Hortobagyi, GN Buzdar, AU Theriault, RL Valero, V Frye, D Booser, DJ Holmes, FA Giralt, S Khouri, I Andersson, B Gajewski, JL Rondon, G Smith, TL Singletary, SE Ames, FC Sneige, N Strom, EA McNeese, MD Deisseroth, AB Champlin, RE
Citation: Gn. Hortobagyi et al., Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma, J NAT CANC, 92(3), 2000, pp. 225-233
Untitled - Response
Authors: Hortobagyi, GN Buzdar, AU
Citation: Gn. Hortobagyi et Au. Buzdar, Untitled - Response, J NAT CANC, 92(15), 2000, pp. 1273-1273
Ductal carcinoma-in-situ: Long-term results of breast-conserving therapy
Authors: Mirza, NQ Vlastos, G Meric, F Sahin, AA Singletary, SE Newman, LA Kuerer, HM Ames, FC Ross, MI Feig, BW Pollock, RE Buchholz, TA McNeese, MD Strom, EA Hortobagyi, GN Hunt, KK
Citation: Nq. Mirza et al., Ductal carcinoma-in-situ: Long-term results of breast-conserving therapy, ANN SURG O, 7(9), 2000, pp. 656-664
Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3N0M0 breast cancer
Authors: Meric, F Mirza, NQ Buzdar, AU Hunt, KK Ames, FC Ross, MI Pollock, RE Newman, LA Feig, BW Strom, EA Buchholz, TA McNeese, MD Hortobagyi, GN Singletary, SE
Citation: F. Meric et al., Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3N0M0 breast cancer, ANN SURG O, 7(6), 2000, pp. 435-440
Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients:The M.D. Anderson experience, with long-term follow-up
Authors: Ibrahim, NK Buzdar, AU Asmar, L Theriault, RL Hortobagyi, GN
Citation: Nk. Ibrahim et al., Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients:The M.D. Anderson experience, with long-term follow-up, ANN ONCOL, 11(12), 2000, pp. 1597-1601
Risultati: 1-25 | 26-50 | 51-74